Literature DB >> 17936955

[Results of ARMYDA-ACS trial show good outcome of 80 mg atorvastatin pretreatment in patients with acute coronary syndromes undergoing early percutaneous coronary intervention].

Aleksandra Michałek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17936955

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN： 0022-9032            Impact factor:   3.108


× No keyword cloud information.
  3 in total

1.  Anti-oxidative stress effect of loading-dose rosuvastatin prior to percutaneous coronary intervention in patients with acute coronary syndrome: a prospective randomized controlled clinical trial.

Authors:  Dong Liang; Qian Zhang; Hexu Yang; Ran Zhang; Wei Yan; Haokao Gao; Jinda Wang; Xiaotian Zhang; Yundai Chen; Feng Cao
Journal:  Clin Drug Investig       Date:  2014-11       Impact factor: 2.859

2.  Cardioprotective Effects of Atorvastatin plus Trimetazidine in Percutaneous Coronary Intervention.

Authors:  Xuefeng Lin; Aiqun Ma; Wei Zhang; Qun Lu; Chaofeng Sun; Hongyan Tian; Xinjun Lei; Xiaojun Bai
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

3.  Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction.

Authors:  Shan-Shan Zhou; Feng Tian; Yun-Dai Chen; Jing Wang; Zhi-Jun Sun; Jun Guo; Qin-Hua Jin
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.